W dniach od 2 kwietnia do 5 kwietnia 2024 r. prowadzone będą prace związane z wdrożeniem nowej wersji systemu Repozytorium UJ. Nie będzie możliwe wprowadzanie nowych informacji do repozytorium. Za utrudnienia przepraszamy.
The mammalian target of rapamycin (mTOR) plays a key role in several cellular processes: proliferation, survival, invasion,
and angiogenesis, and therefore, controls cell behavior both in health and in disease. Dysregulation of the mTOR signaling
is involved in some of the cancer hallmarks, and thus the mTOR pathway is an important target for the development of a new
anticancer therapy. The object of this study is recognition of the possible role of mTOR kinase inhibitors-everolimus single
and in combination with selected downstream protein kinases inhibitors: LY294002 (PI3 K), U0126 (ERK1/2), GDC-0879
(B-RAF), AS-703026 (MEK), MK-2206 (AKT), PLX-4032 (B-RRAF) in cell invasion in malignant melanoma. Treatment
of melanoma cells with everolimus led to a significant decrease in the level of both phosphorylated: mTOR (Ser2448) and
mTOR (Ser2481) as well as their downstream effectors. The use of protein kinase inhibitors produced a significant decrease
in metalloproteinases (MMPs) activity, as well as diminished invasion, especially when used in combination. The best results
in the inhibition of both MMPs and cell invasiveness were obtained for the combination of an mTOR inhibitor- everolimus
with a B-RAF inhibitor-PLX-4032. Slightly less profound reduction of invasiveness was obtained for the combinations of
an mTOR inhibitor-everolimus with ERK1/2 inhibitor-U126 or MEK inhibitor-AS-703026 and in the case of MMPs
activity decrease for PI3 K inhibitor-LY294002 and AKT inhibitor-MK-2206. The simultaneous use of everolimus or
another new generation rapalog with selected inhibitors of crucial signaling kinases seems to be a promising concept in
cancer treatment.
pl
dc.subject.en
melanoma
pl
dc.subject.en
cell invasion
pl
dc.subject.en
protein kinase inhibitors
pl
dc.subject.en
mTOR
pl
dc.description.volume
33
pl
dc.description.number
1
pl
dc.description.points
70
pl
dc.identifier.doi
10.1007/s13577-019-00270-4
pl
dc.identifier.eissn
1749-0774
pl
dc.title.journal
Human Cell
pl
dc.language.container
eng
pl
dc.date.accession
2020-12-28
pl
dc.affiliation
Wydział Lekarski : Zakład Chemii Fizjologicznej
pl
dc.subtype
Article
pl
dc.rights.original
CC-BY; inne; ostateczna wersja wydawcy; w momencie opublikowania; 0